Annual State of Global Market Access

Home / Intelligence / White Papers / Annual State of Global Market Access

In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased implementation of cost-effectiveness policies and the emergence of the consequences of these pricing controls and cost-effectiveness measures, including the Inflation Reduction Act (IRA) and Germany’s Financial Stabilization Act. Regulatory and payer strategies continued to evolve in 2023, and this white paper seeks to illustrate the key consequences of new therapeutic advances and policies aiming to control costs globally and assess their impacts for pharmaceutical manufacturers.

Interested in hearing expert discussion on this white paper?

Register for our
upcoming webinar.

Complete the form below to access the full white paper

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email

Related Intelligence